![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 17, 2023 10:15:45 PM
The FDA or any DSMB isn’t in the business of being impressed by anything. Our sample is just too small to reach statistical significance with the original endpoints of hospitalizations and death even if we would have gotten to 1000 the last 290 or so what have been during the Omicron variant which wouldn’t have helped much, if at all. We haven’t seen the data for the first 210 because at that time the trial was still ongoing but their push to add PCR to the end point as a primary speaks volumes. Add all of the data from Buci’s ugly step sister NAC along with the in vitro studies for Buci show that it should work and work very well. Hindsight is always 20/20 but we would have certainly had the chance to change endpoints and go for an EUA if they would have tracked the symptoms data properly. If we have strong PCR data, symptoms reduction and as a secondary kept folks out of the hospital there will be value here, a lot more than our current market cap which I know isn’t saying much but value none the less!! GLTA
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM